Q0221 HCPCS code: Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg

Q0221 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg. CMS terminated Q0221 on 2024-12-12; do not bill it for later dates of service. In 2023 Medicare paid an average of $0.01 per service for Q0221 across 123 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. Medicare volume fell 97% from 2022 to 2023 (3,840 to 123 services). In 2023, about 69 clinicians billed Medicare for Q0221 for 123 beneficiaries.

Code details

FieldValue
SectionQ codes — Temporary codes
Coverage codeC — Carrier judgment
Pricing indicator54
BETOS categoryO1G — Immunizations/vaccinations
Added2022-02-24
Last action effective2024-12-13
Terminated2024-12-12

Who bills Q0221 (2023)

MeasureValue
Clinicians billing (by place of service)69
Medicare beneficiaries123
States with claims3

Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.

Medicare utilization for Q0221, 2022–2023

YearServicesBeneficiariesAvg. allowedAvg. paid
20223,8403,534$0.01$0.01
2023123123$0.01$0.01

States with the most Q0221 services (2023)

StateServicesAvg. paid
California24$0.01
Pennsylvania17$0.01
Florida12$0.01

What changed for Q0221

Frequently asked questions

What is HCPCS code Q0221?

Q0221 is the HCPCS Level II code for injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg. Short descriptor: "Tixagev and cilgav, 600mg".

How much does Medicare pay for Q0221?

In 2023, the average Medicare payment was $0.01 per service (average allowed $0.01).

Does Medicare cover Q0221?

Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.

Related Q02 codes

Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.

Next steps

Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.

All Q codes · HCPCS lookup